DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Micardis (Telmisartan) - Summary

 
 



WARNING: FETAL TOXICITY

  • When pregnancy is detected, discontinue MICARDIS as soon as possible [see Warnings and Precautions ] .
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions ].
 

MICARDIS SUMMARY

MICARDIS is a non-peptide angiotensin II receptor (type AT1) antagonist.

Hypertension

MICARDIS is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education ProgramÂ’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

It may be used alone or in combination with other antihypertensive agents [see Clinical Studies ] .

CardiovascularRisk Reduction

MICARDIS is indicated for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.

High risk for cardiovascular events can be evidenced by a history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or high-risk diabetes (insulin-dependent or non-insulin dependent) with evidence of end-organ damage [see Clinical Studies ] .  MICARDIS can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy) [see Clinical Studies ] .

Studies of telmisartan in this setting do not exclude the possibility that telmisartan may not preserve a meaningful fraction of the effect of the ACE inhibitor to which it was compared. Consider using the ACE inhibitor first, and, if it is stopped for cough only, consider re-trying the ACE inhibitor after the cough resolves.

Use of telmisartan with an ACE inhibitor is not recommended [see Warnings and Precautions ] .


See all Micardis indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Micardis (Telmisartan)

ESC: Coffee, Naps, and Depression in Hypertension (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2015.08.29]
(MedPage Today) -- Observations support naps but suggest risk with espresso and depression

Medical News Today: Could hypertension during pregnancy signal elevated risk for siblings?
Source: Featured Health News from Medical News Today [2015.08.28]
The male siblings of women who have high blood pressure during pregnancy are at an increased risk of developing cardiovascular disease in later life, a new study finds.

Could hypertension during pregnancy signal elevated risk for siblings?
Source: Biology / Biochemistry News From Medical News Today [2015.08.28]
The male siblings of women who have high blood pressure during pregnancy are at an increased risk of developing cardiovascular disease in later life, a new study finds.

Common 'heart attack' blood test may predict future hypertension
Source: Hypertension News From Medical News Today [2015.08.27]
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressureAnalysis of blood samples from more than 5,000 people suggests that a more sensitive...

ICD-10: Coding for Hypertension and Heart Disease
Source: Medscape Business of Medicine Headlines [2015.08.25]
There are some important elements to be aware of when coding for hypertension, heart disease, and kidney disease in ICD-10.
Medscape Business of Medicine

more news >>

Published Studies Related to Micardis (Telmisartan)

TElmisartan in the management of abDominal aortic aneurYsm (TEDY): The study protocol for a randomized controlled trial. [2015]
BACKGROUND: Experimental studies suggest that angiotensin II plays a central role in the pathogenesis of abdominal aortic aneurysm... TEDY will examine the potential of a promising treatment strategy for patients with small abdominal aortic aneurysms.

A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. [2014]
To determine whether telmisartan improves insulin resistance compared with other antihypertensive drugs, we performed a meta-analysis of randomized controlled trials (RCTs) of telmisartan. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through December 2013...

Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. [2011.11]
The Telmisartan and Losartan Cardiac Evaluation Trial, a multicenter, prospective, randomized, open-labeled, blinded-endpoint trial, was designed to compare the effects of two angiotensin II receptor blockers (ARBs), telmisartan and losartan, on cardiovascular protection in Japanese patients with mild to moderate essential hypertension...

High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-gamma target genes in patients with the metabolic syndrome. [2011.10]
The present study aimed to explore the anti-inflammatory effects and peroxisome proliferator-activated receptor-gamma (PPARgamma)-activating properties of the angiotensin type 1 receptor blocker telmisartan by analysis of serum interleukin 6 levels and monocytic PPARgamma target gene expression in drug-naive patients with the metabolic syndrome...

Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. [2011.03.15]
CONCLUSIONS: This post hoc analysis does not support dual therapy over monotherapy in high-vascular risk patients with low glomerular filtration rate or albuminuria. This observation is a post hoc comparison and should be interpreted appropriately. CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov Identifier: NCT00153101.

more studies >>

Clinical Trials Related to Micardis (Telmisartan)

CKD-828 Drug Interaction Study (Telmisartan) [Completed]
The purpose of this study is to evaluate the Pharmacokinetic drug interaction and safety of Telmisartan between free combination of Telmisartan and S-amlodipine and Telmisartan monotherapy.

Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers [Completed]

A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM) [Completed]
The primary aim of the trial is to compare the influence of MICARDIS® (telmisartan) and COZAAR® / LORZAAR® (losartan) in lowering ambulatory diastolic blood pressure (DBP) during the last 6 hours of the 24-hour dosing interval as measured by ABPM. Secondary objectives include evaluations of: 1) change from baseline in mean systolic blood pressure (SBP) during the last 6 hours of the 24-hour dosing interval as measured by ABPM, 2) changes from baseline in SBP and DBP during other periods during the 24-hour ABPM profile, 3) changes from baseline in mean seated trough SBP and DBP as measured by manual cuff sphygmomanometer, and 4) responder rates based on both ABPM and trough cuff blood pressure

CKD-828 (80/5mg) Pharmacokinetic Study [Completed]
A randomized, open-label, single-dose, two-period, two-way, crossover study to compare the pharmacokinetics and safety CKD-828 (Fixed Dose Combination Tablet) to coadministration telmisartan and s-amlodipine in health volunteers.

more trials >>

Reports of Suspected Micardis (Telmisartan) Side Effects

Dizziness (27)Interstitial Lung Disease (23)Blood Pressure Increased (17)Renal Impairment (17)Hypertension (17)Drug Ineffective (14)Malaise (13)Nausea (13)Headache (12)Dyspepsia (12)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 4 ratings/reviews, Micardis has an overall score of 5. The effectiveness score is 7 and the side effect score is 6.50. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
 

Micardis review by 55 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   hypertension
Dosage & duration:   40 mg taken daily for the period of ongoing, for six months
Other conditions:   diabetes type 2, depression/anxiety
Other drugs taken:   metformin hydrochloride, venlafaxine hydrochloride
  
Reported Results
Benefits:   reduced blood pressure to within acceptable limits. replaced previous drug (ACE inhibitor) with undesirable side effects.
Side effects:   none noticed
Comments:   one tablet daily, in the morning.

 

Micardis review by 51 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Severe Side Effects
  
Treatment Info
Condition / reason:   high blood pressure
Dosage & duration:   80mg a day taken 5 months for the period of 5 months
Other conditions:   None
Other drugs taken:   None
  
Reported Results
Benefits:   Reduced blood pressure. Since takink telmisartan my blood pressure levels went down to normal. I could do my regular activities, including sports.
Side effects:   Reduced sex drive, erectile disfunction. Constant respiratory infection. Since taking telmisartan i have been constantly with intense colds and respiratory tract infections. Plus my sexual drive has reduced considerably. I am not interested in sex and when I had to have sexual relations i experienced difficulty maintaining an erection.
Comments:   Only medication was prescribed. temisartan 80 mg a day. I have benn taking it for more than 5 months.

 

Micardis review by 51 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Severe Side Effects
  
Treatment Info
Condition / reason:   high blood pressure
Dosage & duration:   80mg a day taken 5 months for the period of 5 months
Other conditions:   None
Other drugs taken:   None
  
Reported Results
Benefits:   Reduced blood pressure. Since takink telmisartan my blood pressure levels went down to normal. I could do my regular activities, including sports.
Side effects:   Reduced sex drive, erectile disfunction. Constant respiratory infection. Since taking telmisartan i have been constantly with intense colds and respiratory tract infections. Plus my sexual drive has reduced considerably. I am not interested in sex and when I had to have sexual relations i experienced difficulty maintaining an erection.
Comments:   Only medication was prescribed. temisartan 80 mg a day. I have benn taking it for more than 5 months.

See all Micardis reviews / ratings >>

Page last updated: 2015-08-29

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015